Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense

摘要

Composition for transfection, comprises: (a) a non-viral gene delivery system containing cationic lipid, cationic polymer or a cationic protein, a compound, which exhibits a DNA and/or RNA-binding domain, and/or a compound; and (b) an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense comprising e.g. an antibody against toll-like receptor (TLR) 1 to TLR 13 and cytokine receptor or cytokine receptor-antagonist and an inhibitor of the kinase of mitogen-activated protein kinase 1 (MEK1) and/or MEK2. Composition for transfection, comprises: (a) a non-viral gene delivery system containing a cationic lipid, a cationic polymer or a cationic protein, a compound, which exhibits a DNA and/or RNA-binding domain and activates receptor-mediated endocytosis or a membrane transfer, and/or a compound, which is covalently bonded to DNA and/or RNA and activates receptor-mediated endocytosis or a membrane transfer; and (b) an agent for at least partial suppression and/or activation of the innate intracellular and/or intercellular immune defense comprising an antibody against toll-like receptor (TLR) 1 to TLR 13, an antibody against a cytokine receptor or a cytokine receptor-antagonist, an inhibitor of the kinase of mitogen-activated protein kinase/extracellular signal-regulated kinase 1 (MEK1) and/or MEK2, an agonist for TLR7 and/or TLR8 comprising bropirimine, imidazoquinoline, thiazoloquinoline and/or guanosine analogs. Independent claims are included for: (1) a kit of parts for transfection, comprising the composition; and (2) a procedure for improving the transfection output of non-viral gene delivery system comprising treating the cells with (b), before and/or during the transfection and inserting the transfection genetic material into the cells or treating the cells with (b), before, during and/or after and inserting modified or unmodified small interfering RNA (siRNA) into the cells. ACTIVITY : CNS-Gen.; Respiratory-Gen.; Muscular-Gen.; Metabolic; Antilipemic; Hemostatic; Antianemic; Cytostatic; Virucide; Ophthalmological; Neuroprotective; Antiinflammatory. MECHANISM OF ACTION : Gene therapy.